SCHEMBL724192

SCHEMBL724192

O=S(=O)(Cl)c1ccc(N2CCOCC2)nc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.71
HSD17B10 Q99714 4/20 0.68
SMN1; SMN2 Q16637 3/20 0.63
GAA P10253 5/20 0.56
HPGD P15428 3/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
KDM4E B2RXH2 6/20 0.55
LMNA P02545 3/20 0.54
PKM P14618 1/20 0.54
CNR2 P34972 3/20 0.50
MLNR O43193 2/20 0.50
CYP2D6 P10635 1/20 0.50
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30048936 1.00 ALDH1A1 (0.71) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
Hydrochloric Acid SCHEMBL6197947 0.98 ALDH1A1 (0.69) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
SCHEMBL2651145 0.86 ALDH1A1 (0.73) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
SCHEMBL15049195 0.85 SMN1; SMN2 (0.60) ALDH1A1HSD17B10SMN1; SMN2GAAMEN1
Hydrochloric Acid SCHEMBL28787677 0.84 ALDH1A1 (0.71) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
SCHEMBL13212276 0.84 HSD17B10 (0.72) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
SCHEMBL4370841 0.84 ALDH1A1 (0.71) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
SCHEMBL8230176 0.81 ALDH1A1 (0.66) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
SCHEMBL10154020 0.81 HSD17B10 (0.67) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD
SCHEMBL14101423 0.81 ALDH1A1 (0.66) ALDH1A1HSD17B10SMN1; SMN2GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 EP disclosed
CN-117580830-A Novel pyridine-sulfonamide derivatives as sigma ligands 塔拉森调理公司 2024-02-20 CN disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 WO disclosed
US-20210253598-A1 ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-08-19 US disclosed
EP-3710447-A1 ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES Bayer Aktiengesellschaft (DE) 2020-09-23 EP disclosed
EP-3143021-B1 PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES PFIZER (US) 2019-06-12 EP disclosed
EP-2970215-B1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND (DE) 2019-04-17 EP disclosed
US-9656955-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-23 US disclosed
US-9650334-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-16 US disclosed
WO-2004035577-A2 PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2004-04-29 WO disclosed
WO-2004035576-A2 PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2004-04-29 WO disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166649-A1 Methods for treating arthritic disorders WYETH 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030149029-A1 Methods for treating asthmatic conditions WYETH 2003-08-07 US disclosed
US-20030144282-A1 Inhibitors of cytosolic phospholipase A2 WYETH 2003-07-31 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003048122-A2 INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 WYETH (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 ALDH1A1 1011/4885HSD17B10 3661/4885SMN1; SMN2 3118/4885
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL ALDH1A1 1304/4885HSD17B10 94/4885SMN1; SMN2 4233/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL ALDH1A1 1599/4885HSD17B10 106/4885SMN1; SMN2 4133/4885
US-20030166649-A1 Methods for treating arthritic disorders PLA2G12A, PLA2G4A, PLA2G4B ALDH1A1 304/4885HSD17B10 464/4885SMN1; SMN2 2567/4885
US-20030149029-A1 Methods for treating asthmatic conditions PLA2G4A, PLA2G4B, PLA2G1B ALDH1A1 536/4885HSD17B10 646/4885SMN1; SMN2 3295/4885
US-20210253598-A1 ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES AHR, IDO1, CCNA1 ALDH1A1 280/4885HSD17B10 1748/4885SMN1; SMN2 3685/4885
US-20030144282-A1 Inhibitors of cytosolic phospholipase A2 PLA2G4A, PLA2G4B, PLA2G4C ALDH1A1 1910/4885HSD17B10 1233/4885SMN1; SMN2 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.